Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

doi:10.1158/1078-0432.CCR-10-3137

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2011

Molinari Francesca, Felicioni Lara, Buscarino Michela, De Dosso Sara, Buttitta Fiamma, Malatesta Sara, Movilia Alessandra, Luoni Marco, Boldorini Renzo, Alabiso Oscar, Girlando Salvatore, Soini Barbara, Spitale Alessandra, Di Nicolantonio Federica, Saletti Piercarlo, Crippa Stefano, Mazzucchelli Luca, Marchetti Antonio, Bardelli Alberto, Frattini Milo

Abstract excerpt

PURPOSE: KRAS mutations represent the main cause of resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in metastatic colorectal cancer (mCRC). We evaluated whether highly sensitive methods for KRAS investigation improve the accuracy of predictions of anti-EGFR MoAbs efficacy. EXPERIMENTAL DESIGN: We retrospectively evaluated objective tumor responses in mCRC patients treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Kaplan-Meier Estimate

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to PTEN Phosphohydrolase

Share to ras Proteins

Source

Open in PubMed

Identifiers

PMID: 21632860
DOI: 10.1158/1078-0432.CCR-10-3137

Genes

KRAS
EGFR
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.PMID 21632860Read ↗

Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy.Semantic proximity Read ↗

Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancerSemantic proximity Read ↗

Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.Semantic proximity Read ↗

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.Semantic proximity Read ↗

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.